One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma.
Stinchcombe, Thomas E. MD 1,2,
doi : 10.1200/JCO.22.02720
Volume 41(12) pgs. 2123-2301 April 20, 2023
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.
Vogelzang, Nicholas J.; Rusthoven, James J.; Symanowski, James; Denham, Claude; Kaukel, E.; Ruffie, Pierre; Gatzemeier, Ulrich; Boyer, Michael; Emri, Salih; Manegold, Christian; Niyikiza, Clet; Paoletti, Paolo
doi : 10.1200/JCO.22.02542
Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy.
First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?.
Burtness, Barbara MD 1,
doi : 10.1200/JCO.22.02349
Immunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?.
Ciombor, Kristen K. MD, MSCI 1,,; Eng, Cathy MD 1,
doi : 10.1200/JCO.22.02564
The Intersection of Lung Cancer Screening, Radiomics, and Artificial Intelligence: Can One Scan Really Predict the Future Development of Lung Cancer?.
Silvestri, Gerard A. MD, MS 1,; Jett, James R. MD 2,3,
doi : 10.1200/JCO.22.02885
When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
Esserman, Laura J. MD 1,; Ali, Hirra MD 1; McKenzie, Tesia MD 1
doi : 10.1200/JCO.22.02070
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Racism Does Not Cause Prostate Cancer, It Causes Prostate Cancer Death.
Vickers, Andrew J. PhD 1,; Mahal, Brandon MD 2,; Ogunwobi, Olorunseun O. MBBS, PhD 3,
doi : 10.1200/JCO.22.02203
Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials.
Frankel, Paul H. PhD 1,; Groshen, Susan PhD 2; Beumer, Jan H. PhD, PharmD 3,4,5,; Cleveland, Laura BS 6; Kim, Edward S. MD, MBA 7,; Karp, Judith E. MD 8,
doi : 10.1200/JCO.22.01736
Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.
Bartels, Sanne A.L. MD, PhD, MSc 1,2,; Donker, Mila MD, PhD 2,3; Poncet, Coralie MSc 1; Sauve, Nicolas MSc 1; Straver, Marieke E. MD, PhD 4; van de Velde, Cornelis J.H. MD, PhD 5; Mansel, Robert E. MD, MS 6,; Blanken, Charlotte MD, PhD 7; Orzalesi, Lorenzo MD, PhD 8; Klinkenbijl, Jean H.G. MD, PhD 9; van der Mijle, Huub C.J. MD, PhD 10; Nieuwenhuijzen, Grard A.P. MD, PhD 11; Veltkamp, Sanne C. MD, PhD 12; van Dalen, Thijs MD, PhD 13; Marinelli, Andreas MD, PhD 4; Rijna, Herman MD, PhD 14; Snoj, Marko MD, PhD 15; Bundred, Nigel J. MD, PhD 16,; Merkus, Jos W.S. MD, PhD 17; Belkacemi, Yazid MD, PhD 18,19,; Petignat, Patrick MD 20; Schinagl, Dominic A.X. MD, PhD 21; Coens, Corneel MSc 1; van Tienhoven, Geertjan MD, PhD 22; van Duijnhoven, Frederieke MD, PhD 2; Rutgers, Emiel J.T. MD, PhD 2,
doi : 10.1200/JCO.22.01565
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad, Robert I. MD 1,; Harrington, Kevin MBBS, PhD, FRCP 2; Tahara, Makoto MD, PhD 3; Ferris, Robert L. MD, PhD 4; Gillison, Maura MD, PhD 5; Fayette, Jerome MD, PhD 6; Daste, Amaury MD 7; Koralewski, Piotr MD 8; Zurawski, Bogdan MD 9; Taberna, Miren MD, PhD 10; Saba, Nabil F. MD, FACP 11; Mak, Milena MD, PhD 12; Kawecki, Andrzej MD 13; Girotto, Gustavo MD 14; Alvarez Avitia, Miguel Angel MD 15; Even, Caroline MD 16; Toledo, Joaquin Gabriel Reinoso MD 17; Guminski, Alexander MBBS, PhD, FRACP 18; Muller-Richter, Urs MD, DMD, MDS 19; Kiyota, Naomi MD, PhD 20; Roberts, Mustimbo PhD 21; Khan, Tariq Aziz MD 21; Miller-Moslin, Karen PhD 21; Wei, Li PhD 21; Argiris, Athanassios MD, FACP 22,23
doi : 10.1200/JCO.22.00332
CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil <= six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.
Ludford, Kaysia MD 1,2,; Ho, Won Jin MD 3; Thomas, Jane V. MD 2; Raghav, Kanwal P.S. MBBS 2,; Murphy, Mariela Blum MD 2,; Fleming, Nicole D. MD 4,; Lee, Michael S. MD 2,; Smaglo, Brandon G. MD 2,; You, Y. Nancy MD 5; Tillman, Matthew M. MD 5; Kamiya-Matsuoka, Carlos MD 6; Thirumurthi, Selvi MD 7; Messick, Craig MD 5; Johnson, Benny DO 2,; Vilar, Eduardo MD, PhD 8,; Dasari, Arvind MBBS 2,; Shin, Sarah BS 3; Hernandez, Alexei BS 3; Yuan, Xuan MD 3; Yang, Hongqui 3; Foo, Wai Chin MD 9; Qiao, Wei MS, PhD 10; Maru, Dipen MD 9,; Kopetz, Scott MD, PhD 2,; Overman, Michael J. MD 2,
doi : 10.1200/JCO.22.01351
Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space.
Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography.
Mikhael, Peter G. BSc 1,2; Wohlwend, Jeremy ME 1,2; Yala, Adam PhD 1,2,; Karstens, Ludvig MSc 1,2; Xiang, Justin ME 1,2; Takigami, Angelo K. MD 3,4,; Bourgouin, Patrick P. MD 3,4; Chan, PuiYee PhD 5; Mrah, Sofiane MSc 4; Amayri, Wael BSc 4; Juan, Yu-Hsiang MD 6,7; Yang, Cheng-Ta MD 6,8,; Wan, Yung-Liang MD 6,7; Lin, Gigin MD, PhD 6,7,; Sequist, Lecia V. MD, MPH 3,5,,; Fintelmann, Florian J. MD 3,4,; Barzilay, Regina PhD 1,2,
doi : 10.1200/JCO.22.01345
Low-dose computed tomography (LDCT) for lung cancer screening is effective, although most eligible people are not being screened. Tools that provide personalized future cancer risk assessment could focus approaches toward those most likely to benefit.
Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial.
Meduri, Bruno MD 1,; Baldissera, Antonella MD 2; Iotti, Cinzia MD 3; Scheijmans, Luc J.E.E. MD 4; Stam, Marcel R. MD 5; Parisi, Salvatore MD 6; Boersma, Liesbeth J. MD 7; Ammendolia, Ilario MD 8; Koiter, Eveline MD 9; Valli, Mariacarla MD 10; Scandolaro, Luciano MD 11; Busz, Dianne MD 12; Stenfert Kroese, Marika C. MD 13; Ciabatti, Selena MD 2; Giacobazzi, Patrizia MD 1; Ruggieri, Maria P. PhD 3; Engelen, Antoine MD 4; Munafo, Tindara MD 6; Westenberg, A. Helen MD 5; Verhoeven, Karolien MD 7; Vicini, Roberto PhD 14; D'Amico, Roberto PhD 14,15; Lohr, Frank MD 1,; Bertoni, Filippo MD 1; Poortmans, Philip MD 16,17,; Frezza, Giovanni P. MD 2
doi : 10.1200/JCO.22.01485
The results in terms of side effects vary among the published accelerated partial-breast irradiation (APBI) studies. Here, we report the 5-year results for cosmetic outcomes and toxicity of the IRMA trial.
Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.
Sanchez, Victoria A. AuD, PhD 1,; Shuey, Megan M. PhD 2; Dinh, Paul C. Jr PhD 3; Monahan, Patrick O. PhD 4; Fossa, Sophie D. MD 5; Sesso, Howard D. ScD 6,; Dolan, M. Eileen PhD 7; Einhorn, Lawrence H. MD 3; Vaughn, David J. MD 8; Martin, Neil E. MD 6; Feldman, Darren R. MD 9,; Kroenke, Kurt MD, MACP 10; Fung, Chunkit MD 11,; Frisina, Robert D. PhD 1,; Travis, Lois B. MD, ScD 3,
doi : 10.1200/JCO.22.01456
Cisplatin is widely used and highly ototoxic, but patient-reported functional impairment because of cisplatin-related hearing loss (HL) and tinnitus has not been comprehensively evaluated.
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
Eapen, Mary MBBS, MS 1,; Brazauskas, Ruta PhD 2; Williams, David A. MD 3,; Walters, Mark C. MD 4,; St Martin, Andrew MS 1,; Jacobs, Benjamin L. MS 1,; Antin, Joseph H. MD 5,; Bona, Kira MD 5; Chaudhury, Sonali MD 6; Coleman-Cowger, Victoria H. PhD 7; DiFronzo, Nancy L. PhD 8; Esrick, Erica B. MD 3,; Field, Joshua J. MD, MS 1,; Fitzhugh, Courtney D. MD 9; Kanter, Julie MD 10,; Kapoor, Neena MD 11; Kohn, Donald B. MD 12,; Krishnamurti, Lakshmanan MD 13,; London, Wendy B. PhD 3,; Pulsipher, Michael A. MD 14,; Talib, Sohel MD 15; Thompson, Alexis A. MD 16; Waller, Edmund K. MD, PhD 17,; Wun, Ted MD 18,; Horowitz, Mary M. MD, MS 1,
doi : 10.1200/JCO.22.01203
To report the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease. METHODS: Included are 1,096 transplants for sickle cell disease between 1991 and 2016.
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont, Catherine MD, PhD 1,; Phillips, Tycel MD 2; Ghesquieres, Herve MD, PhD 3; Cheah, Chan Y. MBBS, DMSc 4,5; Clausen, Michael Roost MD, PhD 6; Cunningham, David MD 7; Do, Young Rok MD, PhD 8; Feldman, Tatyana MD 9; Gasiorowski, Robin MBBS, PhD 10; Jurczak, Wojciech MD, PhD 11; Kim, Tae Min MD, PhD 12; Lewis, David John MD 13; van der Poel, Marjolein MD, PhD 14; Poon, Michelle Limei MD 15; Cota Stirner, Mariana MD, PhD 16; Kilavuz, Nurgul MSc 17; Chiu, Christopher PhD 17; Chen, Menghui PhD 17; Sacchi, Mariana MD 17; Elliott, Brian MD 17; Ahmadi, Tahamtan MD, PhD 17; Hutchings, Martin MD, PhD 18; Lugtenburg, Pieternella J. MD, PhD 19
doi : 10.1200/JCO.22.01725
Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells.
Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
Chow, Eric J. MD, MPH 1,; Aggarwal, Sanjeev MD 2; Doody, David R. MS 1; Aplenc, Richard MD, PhD 3,; Armenian, Saro H. DO, MPH 4; Baker, K. Scott MD, MS 1; Bhatia, Smita MD, MPH 5,; Blythe, Nancy BA 1; Colan, Steven D. MD 6,; Constine, Louis S. MD 7,; Freyer, David R. DO, MS 8; Kopp, Lisa M. DO, MPH 9,; Laverdiere, Caroline MD 10; Leisenring, Wendy M. ScD 1,; Sasaki, Nao MD 6; Vrooman, Lynda M. MD 6; Asselin, Barbara L. MD 7; Schwartz, Cindy L. MD, MPH 11; Lipshultz, Steven E. MD 12
doi : 10.1200/JCO.22.02423
For survivors of childhood cancer treated with doxorubicin, dexrazoxane is cardioprotective for at least 5 years. However, longer-term data are lacking.
Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer.
Wu, Natalie L. MD, MS 1,2,3,; Chen, Yan MMath 4; Dieffenbach, Bryan V. MD 5; Ehrhardt, Matthew J. MD, MS 6,; Hingorani, Sangeeta MD, MPH 2,3; Howell, Rebecca M. PhD 7,; Jefferies, John L. MD 8,; Mulrooney, Daniel A. MD, MS 6,; Oeffinger, Kevin C. MD 9; Robison, Leslie L. PhD 6; Weil, Brent R. MD, MPH 5; Yuan, Yan PhD 4; Yasui, Yutaka PhD 6; Hudson, Melissa M. MD 6,; Leisenring, Wendy M. ScD 3,; Armstrong, Gregory T. MD, MSCE 6,; Chow, Eric J. MD, MPH 2,3,
doi : 10.1200/JCO.22.01926
Kidney failure is a rare but serious late effect following treatment for childhood cancer. We developed a model using demographic and treatment characteristics to predict individual risk of kidney failure among 5-year survivors of childhood cancer.
Advancing Survivors Knowledge (ASK Study) of Skin Cancer Surveillance After Childhood Cancer: A Randomized Controlled Trial in the Childhood Cancer Survivor Study.
Geller, Alan C. RN, MPH 1,; Coroiu, Adina PhD 1; Keske, Robyn R. MPH 1; Haneuse, Sebastien PhD 2; Davine, Jessica A. MPH 1; Emmons, Karen M. PhD 1,; Daniel, Casey L. PhD, MPH 1; Gibson, Todd M. PhD 3; McDonald, Aaron J. PhD 4; Robison, Leslie L. PhD 4; Mertens, Ann C. PhD 5; Elkin, Elena B. PhD 6,; Marghoob, Ashfaq MD 7,; Armstrong, Gregory T. MD, MSCE 4,
doi : 10.1200/JCO.22.00408
To improve skin cancer screening among survivors of childhood cancer treated with radiotherapy where skin cancers make up 58% of all subsequent neoplasms. Less than 30% of survivors currently complete recommended skin cancer screening.
Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options.
Reynolds, Anna C. MD 1; McKenzie, Laurie J. MD 1,2,
doi : 10.1200/JCO.22.01885
To review the complex concerns of oncofertility created through increased cancer survivorship and the long-term effects of cancer treatment in young adults.
Wearing Your Heart Around Your Neck: Fostering Physician-Patient Relationships Through Sports.
Wytiaz, Victoria A. MD, MA 1,
doi : 10.1200/JCO.22.02529
Sequencing of Targeted Treatment and Immunotherapy in Advanced BRAF-Mutant Melanoma.
Devlin, Olivia MBBch, BAO; Oladipo, Olabode MBBS, PhD
doi : 10.1200/JCO.22.02250
Reply to O. Devlin et al.
Chandra, Sunandana MD, MS; Choi, Jacob S. MD, PhD; Sosman, Jeffrey A. MD
doi : 10.1200/JCO.22.02468
Cognitive Problems in Older Breast Cancer Survivors.
Yang, Shijie MD; Tan, Meijuan MBBS; Gao, Feng MBBS; Xu, Xiequn MD
doi : 10.1200/JCO.22.02282
Reply to S. Yang et al.
Carroll, Judith E. PhD; Mandelblatt, Jeanne S. MD; Breen, Elizabeth C. PhD
doi : 10.1200/JCO.22.02781
Erratum: Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
doi : 10.1200/JCO.23.00175
Erratum: COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
doi : 10.1200/JCO.23.00385
